US EditionUS FDA approves Gilead's twice-yearly injection for HIV prevention
- On Wednesday, the FDA approved Gilead Sciences' twice-yearly injectable drug lenacapavir, marketed as Yeztugo, for HIV prevention in the U.S.
- Lenacapavir was approved following more than six years of development and extensive clinical trials demonstrating almost complete prevention of HIV when administered as biannual injections.
- The medication is delivered through a pair of abdominal injections that create a slowly releasing reservoir, cutting the required number of yearly medical appointments in half.
- One study in sub-Saharan Africa found zero HIV infections among lenacapavir recipients versus 2% in controls, and experts call it the closest alternative to a vaccine.
- Despite Gilead’s goal to provide access to 2 million people globally, high costs, insurer hurdles, political funding cuts, and health disparities may limit lenacapavir’s reach.
176 Articles
176 Articles
FDA Approves HIV-Prevention Drug That Nearly Eliminated the Virus’s Spread in Clinical Trials
Gilead Sciences announced June 18 that the Food and Drug Administration (FDA) has approved its twice-a-year shot to prevent HIV, with company executives touting the medication as a “very real opportunity” at ending the HIV epidemic. In a press release, Gilead said that clinical trials of the drug—called Yeztugo or lenacapavir—showed that the twice-yearly injection was highly effective, with nearly all study participants who took it remaining HIV…
Reforma
mural.com.mxThe United States approved a new treatment to prevent HIV consisting of two injections at a. o.
Yeztugo prevents HIV with 99.9% effectiveness, but experts warn about access barriers for Latinos in the U.S.
Washington, United States.The U.S. approved a new treatment to prevent HIV, called Yeztugo, announced Wednesday the pharmaceutical laboratory Gilead, which develops it.This treatment called Yeztugo consists of two injections annually and could revolutionize the fight against the Human Immunodeficiency Virus and AIDS.Medicines intended to prevent the transmission of HIV have been in existence for more than a decade, but generally require the taki…
Coverage Details
Bias Distribution
- 65% of the sources are Center
To view factuality data please Upgrade to Premium
